FDA Changes Bioequivalence Requirements For Vancomycin
This article was originally published in The Pink Sheet Daily
ViroPharma, marketer of Lilly’s Vancocin, “strongly disagrees” with FDA’s decision and files a citizen petition challenging it.
You may also be interested in...
The firm, which markets vancomycin hydrochloride, says FDA decision on bioequivalence testing violates FOIA and other statutes.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue